{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:01:02Z","timestamp":1778562062482,"version":"3.51.4"},"reference-count":220,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>During the last decades, male urogenital cancers (including prostate, renal, bladder and testicular cancers) have become one of the most frequently encountered malignancies affecting all ages. While their great variety has promoted the development of various diagnosis, treatment and monitoring strategies, some aspects such as the common involvement of epigenetic mechanisms are still not elucidated. Epigenetic processes have come into the spotlight in the past years as important players in the initiation and progression of tumors, leading to a plethora of studies highlighting their potential as biomarkers for diagnosis, staging, prognosis, and even as therapeutic targets. Thus, fostering research on the various epigenetic mechanisms and their roles in cancer remains a priority for the scientific community. This review focuses on one of the main epigenetic mechanisms, namely, the methylation of the histone H3 at various sites and its involvement in male urogenital cancers. This histone modification presents a great interest due to its modulatory effect on gene expression, leading either to activation (e.g., H3K4me3, H3K36me3) or repression (e.g., H3K27me3, H3K9me3). In the last few years, growing evidence has demonstrated the aberrant expression of enzymes that methylate\/demethylate histone H3 in cancer and inflammatory diseases, that might contribute to the initiation and progression of such disorders. We highlight how these particular epigenetic modifications are emerging as potential diagnostic and prognostic biomarkers or targets for the treatment of urogenital cancers.<\/jats:p>","DOI":"10.3389\/fcell.2023.1181764","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T05:17:40Z","timestamp":1683609460000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["H3 histone methylation landscape in male urogenital cancers: from molecular mechanisms to epigenetic biomarkers and therapeutic targets"],"prefix":"10.3389","volume":"11","author":[{"given":"Liliana","family":"Burlibasa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina-Teodora","family":"Nicu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana Carmen","family":"Chifiriuc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cosmin","family":"Medar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia","family":"Petrescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viorel","family":"Jinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ileana","family":"Stoica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR project GENIE: Powering precision medicine through an international Consortium","volume":"7","year":"2017","journal-title":"Cancer Discov."},{"key":"B2","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"6651","DOI":"10.1158\/0008-5472.CAN-17-0899","article-title":"EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming","volume":"77","author":"Adelaiye-Ogala","year":"2017","journal-title":"Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e1008408","DOI":"10.1371\/journal.pcbi.1008408","article-title":"Bivalent chromatin as a therapeutic target in cancer: An in silico predictive approach for combining epigenetic drugs","volume":"17","author":"Alarc\u00f3n","year":"2021","journal-title":"PLOS Comput. Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrg.2016.59","article-title":"The molecular hallmarks of epigenetic control","volume":"17","author":"Allis","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"53018","DOI":"10.18632\/oncotarget.10061","article-title":"Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer","volume":"7","author":"Almeida-Rios","year":"2016","journal-title":"Oncotarget"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/sj.bjc.6605880","article-title":"Carcinoma in situ testis displays permissive chromatin modifications similar to immature foetal germ cells","volume":"103","author":"Almstrup","year":"2010","journal-title":"Br. J. Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA a cancer J. Clin."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.3390\/cancers13092071","article-title":"The role of epigenetics in the progression of clear cell renal cell carcinoma and the basis for future epigenetic treatments","volume":"13","author":"Angulo","year":"2021","journal-title":"Cancers"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.3390\/cells9071699","article-title":"Regulation of histone ubiquitination in response to DNA double strand breaks","volume":"9","author":"Aquila","year":"2020","journal-title":"Cells"},{"key":"B11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e2114324119","DOI":"10.1073\/pnas.2114324119","article-title":"H3K9 methylation drives resistance to androgen receptor\u2013antagonist therapy in prostate cancer","volume":"119","author":"Baratchian","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3389\/fendo.2019.00343","article-title":"On the origin of testicular germ cell tumors: From gonocytes to testicular cancer","volume":"10","author":"Baroni","year":"2019","journal-title":"Front. Endocrinol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/s41417-021-00327-3","article-title":"PRMT5: A putative oncogene and therapeutic target in prostate cancer","volume":"29","author":"Beketova","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13148-021-01021-9","article-title":"SMYD3: A regulator of epigenetic and signaling pathways in cancer","volume":"13","author":"Bernard","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature05913","article-title":"Perceptions of epigenetics","volume":"447","author":"Bird","year":"2007","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"104654","DOI":"10.18632\/oncotarget.20992","article-title":"Testicular cancer from diagnosis to epigenetic factors","volume":"8","author":"Boccellino","year":"2017","journal-title":"Oncotarget"},{"key":"B19","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/nrurol.2012.185","article-title":"The complexity of prostate cancer: Genomic alterations and heterogeneity","volume":"9","author":"Boyd","year":"2012","journal-title":"Nat. Rev. Urol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3390\/cancers12010201","article-title":"Characterization of the menin-MLL interaction as therapeutic cancer target","volume":"12","author":"Brzezinka","year":"2020","journal-title":"Cancers"},{"key":"B21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1017\/S0967199420000684","article-title":"DNA methyltransferase inhibitors modulate histone methylation: Epigenetic crosstalk between H3K4me3 and DNA methylation during sperm differentiation","volume":"29","author":"Burliba\u015fa","year":"2021","journal-title":"Zygote"},{"key":"B22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.anireprosci.2013.09.003","article-title":"In vivo effects of Trichostatin A - a histone deacetylase inhibitor - on chromatin remodeling during Triturus cristatus spermatogenesis","volume":"142","author":"Burliba\u015fa","year":"2013","journal-title":"Animal Reproduction Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1051046","DOI":"10.1155\/2022\/1051046","article-title":"Environmental factors involved in the high incidence of bladder cancer in an industrialized area in north-eastern Spain","volume":"2022","author":"Caballero","year":"2022","journal-title":"J. Environ. Public Health"},{"key":"B24","doi-asserted-by":"publisher","first-page":"12284","DOI":"10.1038\/ncomms12284","article-title":"Writing of H3K4Me3 overcomes epigenetic silencing in a sustained but context-dependent manner","volume":"7","author":"Cano-Rodriguez","year":"2016","journal-title":"Nat. Commun."},{"key":"B220","unstructured":"A study of CC-90011 and comparators in participants with prostate cancer. last update 20232020"},{"key":"B25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/15592294.2020.1805682","article-title":"Epigenetic alterations as therapeutic targets in Testicular Germ Cell Tumours: Current and future application of \u201cepidrugs","volume":"16","author":"Cardoso","year":"2021","journal-title":"Epigenetics"},{"key":"B26","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1186\/s12885-021-08372-9","article-title":"Significance of KDM6A mutation in bladder cancer immune escape","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1101\/gad.200329.112","article-title":"G9a\/GLP-dependent histone H3K9me2 patterning during human hematopoietic stem cell lineage commitment","volume":"26","author":"Chen","year":"2012","journal-title":"Genes Dev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"8293","DOI":"10.1038\/srep08293","article-title":"Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation","volume":"5","author":"Chen","year":"2015","journal-title":"Sci. Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.bbrc.2008.01.164","article-title":"NGF\/PI3K signaling-mediated epigenetic regulation of delta opioid receptor gene expression","volume":"368","author":"Chen","year":"2008","journal-title":"Biochem. Biophysical Res. Commun."},{"key":"B30","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3892\/ol.2019.10359","article-title":"EZH2 inhibition suppresses bladder cancer cell growth and metastasis via the JAK2\/STAT3 signaling pathway","volume":"18","author":"Chen","year":"2019","journal-title":"Oncol. Lett."},{"key":"B31","doi-asserted-by":"publisher","first-page":"841381","DOI":"10.3389\/fonc.2022.841381","article-title":"The emerging role of PRMT6 in cancer","volume":"12","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"17060","DOI":"10.1074\/jbc.RA120.014704","article-title":"Genetic evidence for partial redundancy between the arginine methyltransferases CARM1 and PRMT6","volume":"295","author":"Cheng","year":"2020","journal-title":"J. Biol. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"789319","DOI":"10.3389\/fphar.2021.789319","article-title":"Comparison of systemic treatments for metastatic castration-resistant prostate cancer after docetaxel failure: A systematic review and network meta-analysis","volume":"12","author":"Chen.","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12935-014-0149-x","article-title":"EHMT2 inhibitor BIX-01294 induces apoptosis through PMAIP1-USP9X-MCL1 axis in human bladder cancer cells","volume":"15","author":"Cui","year":"2015","journal-title":"Cancer Cell Int."},{"key":"B35","doi-asserted-by":"publisher","first-page":"865964","DOI":"10.3389\/fimmu.2022.865964","article-title":"Protein arginine methylation: An emerging modification in cancer immunity and immunotherapy","volume":"13","author":"Dai","year":"2022","journal-title":"Front. Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1158\/1078-0432.CCR-18-0981","article-title":"Randomized phase II study evaluating akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss","volume":"25","author":"de Bono","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"102054","DOI":"10.1016\/j.ctrv.2020.102054","article-title":"Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities","volume":"88","author":"de Vries","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/j.febslet.2010.11.010","article-title":"Histone arginine methylation","volume":"585","author":"Di Lorenzo","year":"2011","journal-title":"FEBS Lett."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1002\/cam4.2152","article-title":"Prognostic role of cyclin D2\/D3 in multiple human malignant neoplasms: A systematic review and meta\u2010analysis","volume":"8","author":"Ding","year":"2019","journal-title":"Cancer Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: A novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1126\/science.aad9512","article-title":"Identification of an NKX3.1-G9a-UTY transcriptional regulatory network that controls prostate differentiation","volume":"352","author":"Dutta","year":"2016","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00345-020-03200-4","article-title":"High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma","volume":"39","author":"Eichenauer","year":"2021","journal-title":"World J. Urology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000355467","article-title":"Alterations of global histone H3K9 and H3K27 methylation levels in bladder cancer","volume":"93","author":"Ellinger","year":"2014","journal-title":"Urol. Int."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1002\/ijc.25250","article-title":"Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma","volume":"127","author":"Ellinger","year":"2010","journal-title":"Int. J. Cancer"},{"key":"B45","unstructured":"A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed\/refractory synovial sarcoma2015"},{"key":"B46","unstructured":"CELLO-1, study of tazemetostat with enzalutamide or abiraterone\/prednisone in subjects with castration resistant prostate cancer who have not received chemotherapy"},{"key":"B47","unstructured":"Tazemetostat expanded access program for adults with solid tumors"},{"key":"B48","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1073\/pnas.0810362106","article-title":"Regulation of DNMT1 stability through SET7-mediated lysine methylation in mammalian cells","volume":"106","author":"Est\u00e8ve","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.18632\/oncotarget.3067","article-title":"NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect","volume":"6","author":"Etani","year":"2015","journal-title":"Oncotarget"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1038\/onc.2012.297","article-title":"The histone methyltransferase MMSET\/WHSC1 activates TWIST1 to promote an epithelial\u2013mesenchymal transition and invasive properties of prostate cancer","volume":"32","author":"Ezponda","year":"2013","journal-title":"Oncogene"},{"key":"B51","doi-asserted-by":"publisher","first-page":"12484","DOI":"10.18632\/oncotarget.14226","article-title":"Epigenetic therapy in urologic cancers: An update on clinical trials","volume":"8","author":"Faleiro","year":"2017","journal-title":"Oncotarget"},{"key":"B52","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13000-019-0901-6","article-title":"PRMT1 expression in renal cell tumors-application in differential diagnosis and prognostic relevance","volume":"14","author":"Filipovi\u0107","year":"2019","journal-title":"Diagn. Pathol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e22290","DOI":"10.1371\/journal.pone.0022290","article-title":"Structural and functional profiling of the human histone methyltransferase SMYD3","volume":"6","author":"Foreman","year":"2011","journal-title":"PLoS ONE"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e15690","DOI":"10.7554\/eLife.15690","article-title":"Set7 mediated Gli3 methylation plays a positive role in the activation of Sonic Hedgehog pathway in mammals","volume":"5","author":"Fu","year":"2016","journal-title":"ELife"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41389-022-00446-y","article-title":"AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer","volume":"12","author":"Fu","year":"2023","journal-title":"Oncogenesis"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1002\/cncr.30597","article-title":"Future of testicular germ cell tumor incidence in the United States: Forecast through 2026","volume":"123","author":"Ghazarian","year":"2017","journal-title":"Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/andr.288","article-title":"Recent trends in the incidence of testicular germ cell tumors in the United States","volume":"3","author":"Ghazarian","year":"2015","journal-title":"Andrology"},{"key":"B58","unstructured":"An open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK3326595 in participants with solid tumors and non-hodgkin's lymphoma (meteor 1)2016"},{"key":"B59","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mrrev.2017.09.003","article-title":"Histone methylation and the DNA damage response","volume":"780","author":"Gong","year":"2019","journal-title":"Mutat. Research\/Reviews Mutat. Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1042\/BCJ20200411","article-title":"Licochalcone A is a natural selective inhibitor of arginine methyltransferase 6","volume":"478","author":"Gong","year":"2020","journal-title":"Biochem. J."},{"key":"B61","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/ijcp.12075","article-title":"Current perspectives in bladder cancer management","volume":"67","author":"Griffiths","year":"2013","journal-title":"Int. J. Clin. Pract."},{"key":"B62","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/cncr.32538","article-title":"Platinum exposure and cause\u2010specific mortality among patients with testicular cancer","volume":"126","author":"Groot","year":"2020","journal-title":"Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"623","DOI":"10.7150\/jca.57663","article-title":"Oncogene or tumor suppressor: The coordinative role of lysine methyltransferase SET7\/9 in cancer development and the related mechanisms","volume":"13","author":"Gu","year":"2022","journal-title":"J. Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41580-019-0155-x","article-title":"The regulation, functions and clinical relevance of arginine methylation","volume":"20","author":"Guccione","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/ng.907","article-title":"Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder","volume":"43","author":"Gui","year":"2011","journal-title":"Nat. Genet."},{"key":"B66","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.eururo.2019.07.002","article-title":"International trends in the incidence of testicular cancer: Lessons from 35 Years and 41 countries","volume":"76","author":"Gurney","year":"2019","journal-title":"Eur. Urol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e27330","DOI":"10.7759\/cureus.27330","article-title":"A review of the etiology and epidemiology of bladder cancer: All you need to know","volume":"14","author":"Halaseh","year":"2022","journal-title":"Cureus"},{"key":"B68","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/cas.12884","article-title":"Dysregulation of protein methyltransferases in human cancer: An emerging target class for anticancer therapy","volume":"107","author":"Hamamoto","year":"2016","journal-title":"Cancer Sci."},{"key":"B69","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/rmb2.12037","article-title":"Fertility preservation of patients with testicular cancer","volume":"16","author":"Hamano","year":"2017","journal-title":"Reproductive Med. Biol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1200\/JCO.21.00637","article-title":"Testicular cancer in the cisplatin era: Causes of death and mortality rates in a population-based cohort","volume":"39","author":"Hellesnes","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fgene.2012.00094","article-title":"The epigenetics of renal cell tumors: From biology to biomarkers","volume":"3","author":"Henrique","year":"2012","journal-title":"Front. Genet."},{"key":"B72","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00345-009-0498-6","article-title":"Deregulation of EZH2 expression in human spermatogenic disorders and testicular germ cell tumors","volume":"28","author":"Hinz","year":"2010","journal-title":"World J. Urology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.bmc.2018.01.031","article-title":"New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells","volume":"26","author":"Hoang","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"B74","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nrd4154","article-title":"Histone lysine demethylases as targets for anticancer therapy","volume":"12","author":"H\u00f8jfeldt","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"B75","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/cncr.20327","article-title":"Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status","volume":"101","author":"Hong","year":"2004","journal-title":"Cancer"},{"key":"B76","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/2211-5463.13579","article-title":"Inhibition of EZH2 exerts antitumorigenic effects in renal cell carcinoma via LATS1","volume":"13","author":"Hong","year":"2023","journal-title":"FEBS Open Bio"},{"key":"B77","doi-asserted-by":"publisher","first-page":"78","DOI":"10.22465\/kjuo.2020.18.2.78","article-title":"Epigenetic approaches to the treatment of renal cell cancer","volume":"18","author":"Hong","year":"2020","journal-title":"Korean J. Urological Oncol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3233\/CBM-160003","article-title":"Different expression patterns of histone H3K27 demethylases in renal cell carcinoma and bladder cancer","volume":"18","author":"Hong","year":"2017","journal-title":"Cancer Biomarkers"},{"key":"B79","doi-asserted-by":"publisher","first-page":"627848","DOI":"10.3389\/fmolb.2020.627848","article-title":"A light-inducible split-dCas9 system for inhibiting the progression of bladder cancer cells by activating p53 and E-cadherin","volume":"7","author":"Huang","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"B80","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ccell.2017.08.005","article-title":"Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency","volume":"32","author":"Hurst","year":"2017","journal-title":"Cancer Cell"},{"key":"B81","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/s12276-021-00613-y","article-title":"Protein arginine methyltransferases: Promising targets for cancer therapy","volume":"53","author":"Hwang","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1038\/emm.2017.11","article-title":"Writing, erasing and reading histone lysine methylations","volume":"49","author":"Hyun","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/35036614","article-title":"Role for the p53 homologue p73 in E2F-1-induced apoptosis","volume":"407","author":"Irwin","year":"2000","journal-title":"Nature"},{"key":"B84","doi-asserted-by":"publisher","first-page":"11637","DOI":"10.1074\/jbc.RA119.008693","article-title":"Biochemical and structural investigations clarify the substrate selectivity of the 2-oxoglutarate oxygenase JMJD6","volume":"294","author":"Islam","year":"2019","journal-title":"J. Biol. Chem."},{"key":"B85","doi-asserted-by":"publisher","first-page":"11491","DOI":"10.1074\/jbc.M115.702092","article-title":"Emodin bidirectionally modulates macrophage polarization and epigenetically regulates macrophage memory","volume":"291","author":"Iwanowycz","year":"2016","journal-title":"J. Biol. Chem."},{"key":"B86","unstructured":"A study of SHR2554 alone or in combination with SHR3680 in the treatment of mCRPC2018"},{"key":"B87","doi-asserted-by":"publisher","first-page":"341","DOI":"10.20517\/jtgg.2021.19","article-title":"Epigenetics in prostate cancer treatment","volume":"5","author":"Jones","year":"2021","journal-title":"J. Transl. Genet. Genomics"},{"key":"B88","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41585-018-0023-z","article-title":"Epigenetics in renal cell cancer: Mechanisms and clinical applications","volume":"15","author":"Joosten","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"11341","DOI":"10.1158\/0008-5472.CAN-06-1570","article-title":"Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence","volume":"66","author":"Kahl","year":"2006","journal-title":"Cancer Res."},{"key":"B90","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0140-6736(09)60491-8","article-title":"Bladder cancer","volume":"374","author":"Kaufman","year":"2009","journal-title":"Lancet"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1002\/cncr.21799","article-title":"Androgen-deprivation therapy as primary treatment for localized prostate cancer: Data from cancer of the prostate strategic urologic research endeavor (CaPSURE)","volume":"106","author":"Kawakami","year":"2006","journal-title":"Cancer"},{"key":"B92","doi-asserted-by":"publisher","first-page":"e4687","DOI":"10.1371\/journal.pone.0004687","article-title":"Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis","volume":"4","author":"Ke","year":"2009","journal-title":"PLoS ONE"},{"key":"B93","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1158\/1535-7163.MCT-18-0141","article-title":"AKT inhibition modulates H3K4 demethylase levels in PTEN-null prostate cancer","volume":"18","author":"Khan","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"B94","doi-asserted-by":"publisher","first-page":"8868","DOI":"10.1093\/nar\/gkv874","article-title":"Cooperation between SMYD3 and PC4 drives a distinct transcriptional program in cancer cells","volume":"43","author":"Kim","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat. Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1172\/JCI78132","article-title":"Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1","volume":"126","author":"Kim","year":"2016","journal-title":"J. Clin. Investigation"},{"key":"B97","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/1471-2407-10-197","article-title":"Differential CARM1 expression in prostate and colorectal cancers","volume":"10","author":"Kim","year":"2010","journal-title":"BMC cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1158\/1078-0432.CCR-19-2230","article-title":"Kdm6a deficiency activates inflammatory pathways, promotes M2 macrophage polarization, and causes bladder cancer in cooperation with p53 dysfunction","volume":"26","author":"Kobatake","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B99","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nrm3327","article-title":"Molecular mechanisms and potential functions of histone demethylases","volume":"13","author":"Kooistra","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.molcel.2007.01.017","article-title":"Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase","volume":"25","author":"Kubicek","year":"2007","journal-title":"Mol. Cell"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1101\/gr.275736.121","article-title":"Decoding the function of bivalent chromatin in development and cancer","volume":"31","author":"Kumar","year":"2021","journal-title":"Genome Res."},{"key":"B102","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.eururo.2021.03.005","article-title":"Recent advances in epigenetic biomarkers and epigenetic targeting in prostate cancer","volume":"80","author":"Kumaraswamy","year":"2021","journal-title":"Eur. Urol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.molcel.2007.12.025","article-title":"Methylation of p53 by set7\/9 mediates p53 acetylation and activity in vivo","volume":"29","author":"Kurash","year":"2008","journal-title":"Mol. Cell"},{"key":"B104","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1365-2605.2010.01063.x","article-title":"Histone methylation is a critical regulator of the abnormal expression of POU5F1 and RASSF1A in testis cancer cell lines: Epigenetics and gene deregulation in testicular cancer","volume":"34","author":"Lambrot","year":"2011","journal-title":"Int. J. Androl."},{"key":"B105","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.mehy.2013.09.005","article-title":"The roles of LSD1-mediated epigenetic modifications in maintaining the pluripotency of bladder cancer stem cells","volume":"81","author":"Lan","year":"2013","journal-title":"Med. Hypotheses"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2741\/4534","article-title":"Epigenetic and risk factors of testicular germ cell tumors a brief review","volume":"22","author":"Landero-Huerta","year":"2017","journal-title":"Front. Biosci."},{"key":"B107","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1126\/science.aba8347","article-title":"Extensive heterogeneity in somatic mutation and selection in the human bladder","volume":"370","author":"Lawson","year":"2020","journal-title":"Science"},{"key":"B108","doi-asserted-by":"publisher","first-page":"5658","DOI":"10.3390\/ijms21165658","article-title":"Histone demethylase KDM7A regulates androgen receptor activity, and its chemical inhibitor TC-E 5002 overcomes cisplatin-resistance in bladder cancer cells","volume":"21","author":"Lee","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B109","doi-asserted-by":"publisher","first-page":"S677","DOI":"10.21037\/tcr.2017.05.41","article-title":"Epigenetic regulation in bladder cancer: Development of new prognostic targets and therapeutic implications","volume":"6","author":"Lee","year":"2017","journal-title":"Transl. Cancer Res."},{"key":"B110","doi-asserted-by":"publisher","first-page":"eaai8312","DOI":"10.1126\/scitranslmed.aai8312","article-title":"Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2","volume":"9","author":"Ler","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"B111","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.5213\/inj.1632752.376","article-title":"Genetic and epigenetic alterations in bladder cancer","volume":"20","author":"Li","year":"2016","journal-title":"Int. Neurourol. J."},{"key":"B112","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3892\/etm.2019.8168","article-title":"MiR 629 targets FOXO3 to promote cell apoptosis in gastric cancer","volume":"19","author":"Li","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"6650781","DOI":"10.1155\/2021\/6650781","article-title":"Histone methyltransferase G9a promotes the development of renal cancer through epigenetic silencing of tumor suppressor gene SPINK5","volume":"2021","author":"Li","year":"2021","journal-title":"Oxidative Med. Cell. Longev."},{"key":"B114","doi-asserted-by":"publisher","first-page":"640700","DOI":"10.3389\/fphys.2021.640700","article-title":"Histone methyltransferase EZH2: A potential therapeutic target for kidney diseases","volume":"12","author":"Li","year":"2021","journal-title":"Front. Physiology"},{"key":"B115","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jcrpr.2018.03.003","article-title":"Prognostic factors of metastatic testicular non-seminomatous germ cell tumors after chemotherapy","volume":"5","author":"Liao","year":"2018","journal-title":"J. Cancer Res. Pract."},{"key":"B116","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1101\/gad.349550.122","article-title":"Histone methyltransferase DOT1L is essential for self-renewal of germline stem cells","volume":"36","author":"Lin","year":"2022","journal-title":"Genes Dev."},{"key":"B117","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/andr.304","article-title":"Common variants identified in genome-wide association studies of testicular germ cell tumour: An update, biological insights and clinical application","volume":"3","author":"Litchfield","year":"2015","journal-title":"Andrology"},{"key":"B118","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1093\/nar\/gkaa065","article-title":"PRMT5-mediated histone arginine methylation antagonizes transcriptional repression by polycomb complex PRC2","volume":"48","author":"Liu","year":"2020","journal-title":"Nucleic acids Res."},{"key":"B119","doi-asserted-by":"publisher","first-page":"5081","DOI":"10.1093\/nar\/gkv379","article-title":"Repression of hypoxia-inducible factor \u03b1 signaling by Set7-mediated methylation","volume":"43","author":"Liu","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B120","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.urolonc.2017.10.028","article-title":"High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer","volume":"36","author":"Lobo","year":"2018","journal-title":"Urologic Oncol. Seminars Orig. Investigations"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/brv.12701","article-title":"The effects of endocrine disruptors on the male germline: An intergenerational health risk","volume":"96","author":"Lomb\u00f3","year":"2021","journal-title":"Biol. Rev."},{"key":"B122","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/life12020264","article-title":"Ki67 and LSD1 expression in testicular germ cell tumors is not associated with patient outcome: Investigation using a digital pathology algorithm","volume":"12","author":"Louren\u00e7o","year":"2022","journal-title":"Life"},{"key":"B123","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41419-022-04983-7","article-title":"Histone H3K36me2 demethylase KDM2A promotes bladder cancer progression through epigenetically silencing RARRES3","volume":"13","author":"Lu","year":"2022","journal-title":"Cell Death Dis."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41388-017-0026-x","article-title":"Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4","volume":"37","author":"Lv","year":"2018","journal-title":"Oncogene"},{"key":"B125","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nm.3830","article-title":"Targeting the MLL complex in castration-resistant prostate cancer","volume":"21","author":"Malik","year":"2015","journal-title":"Nat. Med."},{"key":"B126","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/nrm1761","article-title":"The diverse functions of histone lysine methylation","volume":"6","author":"Martin","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3389\/fgene.2019.01125","article-title":"Epigenetics of bladder cancer: Where biomarkers and therapeutic targets meet","volume":"10","author":"Martinez","year":"2019","journal-title":"Front. Genet."},{"key":"B128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/B978-0-12-809552-2.00002-4","article-title":"Role of epigenetics in testicular cancer","volume-title":"Epigenetic mechanisms in cancer","author":"Martinot","year":"2018"},{"key":"B129","unstructured":"DS3201 and ipilimumab for the treatment of metastatic prostate, urothelial and renal cell cancers2020"},{"key":"B130","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3233\/BLC-211609","article-title":"Role of chromatin modifying complexes and therapeutic opportunities in bladder cancer","volume":"8","author":"Meghani","year":"2022","journal-title":"Bladder Cancer"},{"key":"B131","first-page":"453","article-title":"Molecular biology of castration-resistant prostate cancer: Basis for the novel therapeutic targets","volume":"66","author":"Mellado","year":"2013","journal-title":"Arch. Espanoles De. Urol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcancer.2012.06.006","article-title":"An overview of renal cell cancer: Pathology and genetics","volume":"23","author":"Moch","year":"2013","journal-title":"Seminars Cancer Biol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"113031","DOI":"10.1016\/j.biopha.2022.113031","article-title":"G9a inhibition by CM-272: Developing a novel anti-tumoral strategy for castration-resistant prostate cancer using 2D and 3D in vitro models","volume":"150","author":"Moreira-Silva","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"B134","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.92830","article-title":"Discovery of small molecule inhibitors for histone methyltransferases in cancer","volume-title":"Translational research in cancer","author":"Motolani","year":"2021"},{"key":"B135","doi-asserted-by":"publisher","first-page":"e1253","DOI":"10.1002\/cti2.1253","article-title":"Lysine methyltransferase G9a is an important modulator of trained immunity","volume":"10","author":"Mourits","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13148-021-01223-1","article-title":"Therapeutical interference with the epigenetic landscape of germ cell tumors: A comparative drug study and new mechanistical insights","volume":"14","author":"M\u00fcller","year":"2022","journal-title":"Clin. Epigenetics"},{"key":"B137","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ajur.2020.05.009","article-title":"Molecular and epigenetic pathogenesis of germ cell tumors","volume":"8","author":"M\u00fcller","year":"2021","journal-title":"Asian J. Urology"},{"key":"B219","doi-asserted-by":"publisher","first-page":"e1608","DOI":"10.1038\/cddis.2014.569","article-title":"NF-\u03baB-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT","volume":"6","author":"Nakshatri","year":"2015","journal-title":"Cell death and disease"},{"key":"B138","unstructured":"Testing the addition of tazemetostat to the immunotherapy drug, pembrolizumab (MK-3475), in advanced urothelial carcinoma2019"},{"key":"B139","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12885-017-3256-y","article-title":"Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression","volume":"17","author":"Ngollo","year":"2017","journal-title":"BMC Cancer"},{"key":"B140","doi-asserted-by":"publisher","first-page":"861995","DOI":"10.3389\/fcell.2022.861995","article-title":"Epigenetics and testicular cancer: Bridging the gap between fundamental biology and patient care","volume":"10","author":"Nicu","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ydbio.2007.05.002","article-title":"Developmental acquisition of genome-wide DNA methylation occurs prior to meiosis in male germ cells","volume":"307","author":"Oakes","year":"2007","journal-title":"Dev. Biol."},{"key":"B142","unstructured":"Phenelzine sulfate and docetaxel in treating patients with prostate cancer with progressive disease after first-line therapy with docetaxel2010"},{"key":"B143","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/14737140.2018.1450630","article-title":"Therapeutic approaches for refractory germ cell cancer","volume":"18","author":"Oing","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B144","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.pharmthera.2013.01.007","article-title":"Manipulating the epigenome for the treatment of urological malignancies","volume":"138","author":"O\u2019Rourke","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"B145","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1080\/15592294.2021.1939477","article-title":"Epigenetic editing in prostate cancer: Challenges and opportunities","volume":"17","author":"Pacheco","year":"2022","journal-title":"Epigenetics"},{"key":"B146","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1158\/1078-0432.CCR-21-0024","article-title":"A randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone-sensitive prostate cancer","volume":"27","author":"Palmbos","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B147","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/pros.23271","article-title":"P110\u03b2 inhibition reduces histone H3K4 di-methylation in prostate cancer: Pi3K modulates histone methylation","volume":"77","author":"Pang","year":"2017","journal-title":"Prostate"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1158\/0008-5472.CAN-20-1807","article-title":"JMJD6 is a druggable oxygenase that regulates AR-V7 expression in prostate cancer","volume":"81","author":"Paschalis","year":"2021","journal-title":"Cancer Res."},{"key":"B149","unstructured":"PF-06821497 treatment of relapsed\/refractory SCLC, castration resistant prostate cancer, and follicular lymphoma2018"},{"key":"B150","unstructured":"A dose escalation study of PF-06939999 in participants with advanced or metastatic solid tumors2019"},{"key":"B151","doi-asserted-by":"publisher","first-page":"eabo8043","DOI":"10.1126\/sciadv.abo8043","article-title":"Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma","volume":"8","author":"Piunti","year":"2022","journal-title":"Sci. Adv."},{"key":"B152","doi-asserted-by":"publisher","first-page":"151956","DOI":"10.1016\/j.anndiagpath.2022.151956","article-title":"Inverse co-expression of EZH2 and acetylated H3K27 in prostatic tissue","volume":"59","author":"Puzyrenko","year":"2022","journal-title":"Ann. Diagnostic Pathology"},{"key":"B153","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12863-021-01022-w","article-title":"Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker","volume":"23","author":"Qiu","year":"2022","journal-title":"BMC Genom Data"},{"key":"B154","doi-asserted-by":"publisher","first-page":"84775","DOI":"10.18632\/oncotarget.12476","article-title":"Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma","volume":"7","author":"Qu","year":"2016","journal-title":"Oncotarget"},{"key":"B155","doi-asserted-by":"publisher","first-page":"e46821","DOI":"10.15252\/embr.201846821","article-title":"The lysine\u2010specific methyltransferase KMT 2C\/MLL 3 regulates DNA repair components in cancer","volume":"20","author":"Rampias","year":"2019","journal-title":"EMBO Rep."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"174","author":"Robertson","year":"2018","journal-title":"Cell"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"B158","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.2147\/DDDT.S69433","article-title":"Enzalutamide for the treatment of metastatic castration-resistant prostate cancer","volume":"9","author":"Rodriguez-Vida","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"B159","first-page":"879","article-title":"Decreased levels of histone H3K9me1 indicate poor prognosis in patients with renal cell carcinoma","volume":"32","author":"Rogenhofer","year":"2012","journal-title":"Anticancer Res."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.bbagrm.2014.02.007","article-title":"Understanding the relationship between DNA methylation and histone lysine methylation","volume":"1839","author":"Rose","year":"2014","journal-title":"Biochimica Biophysica Acta (BBA) - Gene Regul. Mech."},{"key":"B161","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40610-018-0095-9","article-title":"Epigenetic regulation in prostate cancer progression","volume":"4","author":"Ruggero","year":"2018","journal-title":"Curr. Mol. Biol. Rep."},{"key":"B162","unstructured":"Phase 1 trial of the LSD1 inhibitor SP-2577 (seclidemstat) in patients with advanced solid tumors2019"},{"key":"B163","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.3390\/cancers14194761","article-title":"EZH2 inhibition and cisplatin as a combination anticancer therapy: An overview of preclinical studies","volume":"14","author":"Samar\u017eija","year":"2022","journal-title":"Cancers"},{"key":"B164","doi-asserted-by":"publisher","first-page":"6565","DOI":"10.1158\/0008-5472.CAN-14-1218","article-title":"In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer","volume":"74","author":"Santos","year":"2014","journal-title":"Cancer Res."},{"key":"B165","doi-asserted-by":"publisher","first-page":"E290","DOI":"10.1111\/j.1464-410X.2011.10203.x","article-title":"Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer","volume":"108","author":"Schneider","year":"2011","journal-title":"BJU Int."},{"key":"B166","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.2353\/ajpath.2009.080874","article-title":"Global levels of histone modifications predict prognosis in different cancers","volume":"174","author":"Seligson","year":"2009","journal-title":"Am. J. Pathology"},{"key":"B167","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev-biochem-051710-134100","article-title":"The COMPASS family of histone H3K4 methylases: Mechanisms of regulation in development and disease pathogenesis","volume":"81","author":"Shilatifard","year":"2012","journal-title":"Annu. Rev. Biochem."},{"key":"B168","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.mrfmmm.2008.07.010","article-title":"Roles of the EZH2 histone methyltransferase in cancer epigenetics","volume":"647","author":"Simon","year":"2008","journal-title":"Mutat. Research\/Fundamental Mol. Mech. Mutagen."},{"key":"B169","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.3390\/cancers13071506","article-title":"Between a rock and a hard place: An epigenetic-centric view of testicular germ cell tumors","volume":"13","author":"Singh","year":"2021","journal-title":"Cancers"},{"key":"B170","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1158\/1541-7786.MCR-14-0273","article-title":"Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer","volume":"13","author":"Sowalsky","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"B171","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/j.ajpath.2014.05.022","article-title":"KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy","volume":"184","author":"Stein","year":"2014","journal-title":"Am. J. Pathology"},{"key":"B172","doi-asserted-by":"publisher","first-page":"108924","DOI":"10.1016\/j.biopha.2019.108924","article-title":"KMT2D inhibits the growth and metastasis of bladder Cancer cells by maintaining the tumor suppressor genes","volume":"115","author":"Sun","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"B173","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"B174","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1038\/emboj.2008.192","article-title":"G9a\/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription","volume":"27","author":"Tachibana","year":"2008","journal-title":"EMBO J."},{"key":"B175","doi-asserted-by":"publisher","first-page":"TPS398","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS398","article-title":"A phase 1b\/2 study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone\/prednisone (A\/P) in patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"36","author":"Taplin","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B176","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"key":"B177","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","year":"2015","journal-title":"Cell"},{"key":"B178","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccell.2020.08.009","article-title":"SETting up for epigenetic regulation of advanced prostate cancer","volume":"38","author":"Thienger","year":"2020","journal-title":"Cancer Cell"},{"key":"B179","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1128\/MCB.00099-14","article-title":"The hypoxia-inducible epigenetic regulators Jmjd1a and G9a provide a mechanistic link between angiogenesis and tumor growth","volume":"34","author":"Ueda","year":"2014","journal-title":"Mol. Cell. Biol."},{"key":"B180","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.3390\/cancers12123755","article-title":"Origin of subsequent malignant neoplasms in patients with history of testicular germ cell tumor","volume":"12","author":"Umbreit","year":"2020","journal-title":"Cancers"},{"key":"B181","doi-asserted-by":"publisher","first-page":"100006","DOI":"10.1016\/j.crchbi.2021.100006","article-title":"Benefits and pitfalls: Epigenetic modulators in prostate cancer intervention","volume":"1","author":"Upadhyay","year":"2021","journal-title":"Curr. Res. Chem. Biol."},{"key":"B182","unstructured":"A study of CPI-0209 in patients with advanced solid tumors and lymphomas2019"},{"key":"B183","doi-asserted-by":"publisher","first-page":"e98330","DOI":"10.1371\/journal.pone.0098330","article-title":"Seminoma and embryonal carcinoma footprints identified by analysis of integrated genome-wide epigenetic and expression profiles of germ cell cancer cell lines","volume":"9","author":"van der Zwan","year":"2014","journal-title":"PLoS ONE"},{"key":"B184","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1093\/ije\/dys068","article-title":"Cohort profile: The national prostate cancer register of Sweden and prostate cancer data base Sweden 2.0","volume":"42","author":"Van Hemelrijck","year":"2013","journal-title":"Int. J. Epidemiol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1038\/s41467-020-18013-7","article-title":"Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer","volume":"11","author":"Vatapalli","year":"2020","journal-title":"Nat. Commun."},{"key":"B186","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fendo.2012.00150","article-title":"Epigenetic: A molecular link between testicular cancer and environmental exposures","volume":"3","author":"Vega","year":"2012","journal-title":"Front. Endocrinol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"13644","DOI":"10.18632\/oncotarget.3767","article-title":"SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3","volume":"6","author":"Vieira","year":"2015","journal-title":"Oncotarget"},{"key":"B188","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1530\/ERC-13-0375","article-title":"Deregulated expression of selected histone methylases and demethylases in prostate carcinoma","volume":"21","author":"Vieira","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"B189","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1038\/onc.2017.13","article-title":"Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1\u03b1","volume":"36","author":"Wan","year":"2017","journal-title":"Oncogene"},{"key":"B190","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.3390\/biomedicines10081872","article-title":"Developing new treatment options for castration-resistant prostate cancer and recurrent disease","volume":"10","author":"Wang","year":"2022","journal-title":"Biomedicines"},{"key":"B191","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.21873\/anticanres.12957","article-title":"Transcriptomic analysis of histone methyltransferase Setd7 knockdown and phenethyl isothiocyanate in human prostate cancer cells","volume":"38","author":"Wang","year":"2018","journal-title":"Anticancer Res."},{"key":"B192","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.1158\/0008-5472.CAN-11-0896","article-title":"Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties","volume":"71","author":"Wang","year":"2011","journal-title":"Cancer Res."},{"key":"B193","doi-asserted-by":"publisher","first-page":"5387","DOI":"10.7150\/thno.42345","article-title":"PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma","volume":"12","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"B194","doi-asserted-by":"publisher","first-page":"5755","DOI":"10.1158\/0008-5472.CAN-17-0150","article-title":"PADI2-Mediated citrullination promotes prostate cancer progression","volume":"77","author":"Wang","year":"2017","journal-title":"Cancer Res."},{"key":"B195","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.gendis.2019.10.018","article-title":"Epigenetic regulation of prostate cancer","volume":"7","author":"Wang","year":"2020","journal-title":"Genes Dis."},{"key":"B196","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3389\/fonc.2019.00721","article-title":"LSD1 activates PI3K\/AKT signaling through regulating p85 expression in prostate cancer cells","volume":"9","author":"Wang","year":"2019","journal-title":"Front. Oncol."},{"key":"B197","doi-asserted-by":"publisher","first-page":"S137","DOI":"10.1016\/j.jpeds.2006.06.064","article-title":"Epigenetic mechanisms and gastrointestinal development","volume":"149","author":"Waterland","year":"2006","journal-title":"J. Pediatr."},{"key":"B198","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41420-018-0035-8","article-title":"BIX-01294 sensitizes renal cancer Caki cells to TRAIL-induced apoptosis through downregulation of survivin expression and upregulation of DR5 expression","volume":"4","author":"Woo","year":"2018","journal-title":"Cell Death Discov."},{"key":"B199","doi-asserted-by":"publisher","first-page":"560487","DOI":"10.3389\/fonc.2020.560487","article-title":"Small molecules targeting HATs, HDACs, and BRDs in cancer therapy","volume":"10","author":"Wu","year":"2020","journal-title":"Front. Oncol."},{"key":"B200","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.18632\/oncotarget.6380","article-title":"Novel variants in MLL confer to bladder cancer recurrence identified by whole-exome sequencing","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"B201","doi-asserted-by":"publisher","first-page":"8125","DOI":"10.2147\/CMAR.S213885","article-title":"Effect of SMYD3 on biological behavior and H3K4 methylation in bladder cancer","volume":"11","author":"Wu","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"B202","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/cr.2007.83","article-title":"JMJD3 is a histone H3K27 demethylase","volume":"17","author":"Xiang","year":"2007","journal-title":"Cell Res."},{"key":"B203","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/nature01378","article-title":"Structure and catalytic mechanism of the human histone methyltransferase SET7\/9","volume":"421","author":"Xiao","year":"2003","journal-title":"Nature"},{"key":"B204","doi-asserted-by":"publisher","first-page":"e2200753119","DOI":"10.1073\/pnas.2200753119","article-title":"A specific JMJD6 inhibitor potently suppresses multiple types of cancers both in vitro and in vivo","volume":"119","author":"Xiao","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B205","doi-asserted-by":"publisher","first-page":"8377","DOI":"10.7150\/thno.37628","article-title":"Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma","volume":"9","author":"Yan","year":"2019","journal-title":"Theranostics"},{"key":"B206","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3390\/biology10070581","article-title":"Histone H3K4 methyltransferases as targets for drug-resistant cancers","volume":"10","author":"Yang","year":"2021","journal-title":"Biology"},{"key":"B207","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.3390\/cancers12071736","article-title":"SETD1A promotes proliferation of castration-resistant prostate cancer cells via FOXM1 transcription","volume":"12","author":"Yang","year":"2020","journal-title":"Cancers"},{"key":"B208","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s13238-013-2093-2","article-title":"EZH2, an epigenetic driver of prostate cancer","volume":"4","author":"Yang","year":"2013","journal-title":"Protein Cell"},{"key":"B209","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12916-022-02470-6","article-title":"Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: A prospective, open-label, single-arm phase 2 study (PATHER2)","volume":"2","author":"Yang","year":"2022","journal-title":"J. Natl. Cancer Cent."},{"key":"B210","doi-asserted-by":"publisher","first-page":"6605","DOI":"10.1158\/1078-0432.CCR-14-0257","article-title":"Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival","volume":"20","author":"Yap","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B211","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1128\/MCB.00631-13","article-title":"LSD1 regulates pluripotency of embryonic stem\/carcinoma cells through histone deacetylase 1-mediated deacetylation of histone H4 at lysine 16","volume":"34","author":"Yin","year":"2014","journal-title":"Mol. Cell. Biol."},{"key":"B212","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ccell.2020.05.022","article-title":"SETD2 restricts prostate cancer metastasis by integrating EZH2 and AMPK signaling pathways","volume":"38","author":"Yuan","year":"2020","journal-title":"Cancer Cell"},{"key":"B213","doi-asserted-by":"publisher","first-page":"7983","DOI":"10.1074\/jbc.M110.194027","article-title":"H3K36 methylation antagonizes PRC2-mediated H3K27 methylation","volume":"286","author":"Yuan","year":"2011","journal-title":"J. Biol. Chem."},{"key":"B214","doi-asserted-by":"publisher","first-page":"e1009366","DOI":"10.1371\/journal.ppat.1009366","article-title":"JMJD6 negatively regulates cytosolic RNA induced antiviral signaling by recruiting RNF5 to promote activated IRF3 K48 ubiquitination","volume":"17","author":"Zhang","year":"2021","journal-title":"PLOS Pathog."},{"key":"B215","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.7150\/thno.55814","article-title":"WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer","volume":"11","author":"Zhou","year":"2021","journal-title":"Theranostics"},{"key":"B216","doi-asserted-by":"publisher","first-page":"S469","DOI":"10.21037\/tau.2019.10.07","article-title":"Enhancing response to immunotherapy in urothelial carcinoma by targeted inhibition of the histone methyltransferase G9a pathway","volume":"8","author":"Zhu","year":"2019","journal-title":"Transl. Androl. urology"},{"key":"B217","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.3390\/pharmaceutics14112414","article-title":"PAD4 and its inhibitors in cancer progression and prognosis","volume":"14","author":"Zhu","year":"2022","journal-title":"Pharmaceutics"},{"key":"B218","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1158\/0008-5472.CAN-10-3573","article-title":"Epigenetic silencing mediated through activated PI3K\/AKT signaling in breast cancer","volume":"71","author":"Zuo","year":"2011","journal-title":"Cancer Res."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2023.1181764\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T05:17:50Z","timestamp":1683609470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2023.1181764\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":220,"alternative-id":["10.3389\/fcell.2023.1181764"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2023.1181764","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]},"article-number":"1181764"}}